menu
    • menu
    [{"orgOrder":0,"company":"Cancer Targeted Technology","sponsor":"University of California, San Francisco | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"CTT1403","moa":"Glutamate carboxypeptidase II (GCPII)","graph1":"Oncology","graph2":"Phase I","graph3":"Cancer Targeted Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cancer Targeted Technology \/ University of California, San Francisco | National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Cancer Targeted Technology \/ University of California, San Francisco | National Cancer Institute"},{"orgOrder":0,"company":"Cancer Targeted Technology","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"CTT1403","moa":"Glutamate carboxypeptidase II (GCPII)","graph1":"Oncology","graph2":"Phase I","graph3":"Cancer Targeted Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cancer Targeted Technology \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Cancer Targeted Technology \/ National Institutes of Health"},{"orgOrder":0,"company":"Cancer Targeted Technology","sponsor":"University of California, San Francisco","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"CTT1057","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Cancer Targeted Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cancer Targeted Technology \/ University of California, San Francisco","highestDevelopmentStatusID":"6","companyTruncated":"Cancer Targeted Technology \/ University of California, San Francisco"},{"orgOrder":0,"company":"Cancer Targeted Technology","sponsor":"University of California, San Francisco","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"CTT1057","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Cancer Targeted Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cancer Targeted Technology \/ University of California, San Francisco","highestDevelopmentStatusID":"6","companyTruncated":"Cancer Targeted Technology \/ University of California, San Francisco"},{"orgOrder":0,"company":"Cancer Targeted Technology","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"CTT2274","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cancer Targeted Technology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cancer Targeted Technology \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"5","companyTruncated":"Cancer Targeted Technology \/ The Division of Cancer Treatment and Diagnosis"}]

    Find Clinical Drug Pipeline Developments & Deals by Cancer Targeted Technology

    Menu

    Cancer Targeted Technology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cancer Targeted Technology

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Cancer Targeted Technology

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTT2274

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : The Division of Cancer Treatment and Diagnosis

                            Deal Size : $2.4 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Cancer Targeted Technology Receives $2.4M Grant for PSMA-Targeted Drug Conjugate

                            Details : The funding will be used to develop a new prodrug, CTT2274, that targets PSMA on prostate cancer and is designed to release a toxic drug, MMAE, within the cell that takes up the prodrug.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 18, 2024

                            Lead Product(s) : CTT2274

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : The Division of Cancer Treatment and Diagnosis

                            Deal Size : $2.4 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cancer Targeted Technology

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Cancer Targeted Technology

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTT1403

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : National Institutes of Health

                            Deal Size : $1.4 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            NIH Grants $1.44M to Cancer Targeted Technology to Support the Ongoing Prostate Cancer Clinical Trial of a Pro...

                            Details : The trial is designed to show safety and efficacy of CTT1403 and is halfway through the initial dose escalation phase. CTT1403 targets Prostate Specific Membrane Antigen (PSMA) which is over-expressed on prostate cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 07, 2020

                            Lead Product(s) : CTT1403

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : National Institutes of Health

                            Deal Size : $1.4 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cancer Targeted Technology

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Cancer Targeted Technology

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTT1403

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : University of California, San Francisco | National Cancer Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer

                            Details : CTT1403 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 30, 2019

                            Lead Product(s) : CTT1403

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : University of California, San Francisco | National Cancer Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cancer Targeted Technology

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Cancer Targeted Technology

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTT1057

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : University of California, San Francisco

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Car...

                            Details : CTT1057 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Renal Cell.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 09, 2018

                            Lead Product(s) : CTT1057

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : University of California, San Francisco

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cancer Targeted Technology

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Cancer Targeted Technology

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTT1057

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : University of California, San Francisco

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057

                            Details : CTT1057 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 27, 2016

                            Lead Product(s) : CTT1057

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : University of California, San Francisco

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth